TEVA Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Zacks Investment Research - Mentions: SNY ANIP CSTL

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia

2 days ago - By: The Motley Fool - Mentions: ALIT CVS THC GPN ...

Glenview Capital Management Sells $71 Million of Alight Stake After Stock's 71% Drop

2 days ago - By: Zacks Investment Research - Mentions: SNY BMY NVO

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

2 days ago - By: The Motley Fool - Mentions: CVS THC GPN GTM

Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing

3 days ago - By: Teva Pharmaceutical Industries Ltd

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

4 days ago - By: Zacks Investment Research - Mentions: RDY

3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape

6 days ago - By: Zacks Investment Research - Mentions: SNY FOLD

Can Galafold Continue to Drive Amicus' Top Line in 2026?

3 days ago - By: Teva Pharmaceutical Industries Ltd

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

3 days ago - By: Zacks Investment Research - Mentions: RDY

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's

3 days ago - By: Zacks Investment Research - Mentions: JNJ AMGN

Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

9 days ago - By: Zacks Investment Research

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

a month ago - By: Benzinga

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today

a month ago - By: Benzinga

Price Over Earnings Overview: Teva Pharmaceutical Indus

15 days ago - By: Stocktwits - Mentions: LABU NVO ABBV AZN ...

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared

15 days ago - By: Stocktwits - Mentions: NVO LLY GSK PFE ...

JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets

15 days ago - By: Investor's Business Daily - Mentions: RY RY.CA NVO NBIX ...

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied

16 days ago - By: Teva Pharmaceutical Industries Ltd

Teva erhält Zulassung der Europäischen Kommission für PONLIMSI® (Denosumab), ein Biosimilar zu Prolia®, und DEGEVMA® (Denosumab), ein Biosimilar zu Xgeva®

16 days ago - By: Teva Pharmaceutical Industries Ltd

Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva®

17 days ago - By: Teva Pharmaceutical Industries Ltd

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

17 days ago - By: Teva Pharmaceutical Industries Ltd

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

20 days ago - By: Teva Pharmaceutical Industries Ltd

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

20 days ago - By: Teva Pharmaceutical Industries Ltd

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

23 days ago - By: Teva Pharmaceutical Industries Ltd

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

a month ago - By: Zacks Investment Research - Mentions: ANIP AMRX VTRS

ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?

a month ago - By: Zacks Investment Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

a month ago - By: Zacks Investment Research

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

a month ago - By: Teva Pharmaceutical Industries Ltd

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

a month ago - By: Teva Pharmaceutical Industries Ltd

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

a month ago - By: Zacks Investment Research - Mentions: BWAY

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

a month ago - By: Zacks Investment Research - Mentions: ANIP SNDX ARQT

TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock News

TEVA Latest News, Press Relases and Analysis

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia

Glenview Capital Management Sells $71 Million of Alight Stake After Stock's 71% Drop

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape

Can Galafold Continue to Drive Amicus' Top Line in 2026?

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's

Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today

Price Over Earnings Overview: Teva Pharmaceutical Indus

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared

JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied

Teva erhält Zulassung der Europäischen Kommission für PONLIMSI® (Denosumab), ein Biosimilar zu Prolia®, und DEGEVMA® (Denosumab), ein Biosimilar zu Xgeva®

Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva®

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up